Connect with us

Hi, what are you looking for?

BioTechnology

TCT 2021: Patients with Diabetes Undergoing PCI Have Less Target Lesion Failure with Amphilimus-Eluting Stents

The primary endpoint was target-lesion failure at one year, a composite of cardiac death, target-vessel myocardial infarction (MI), and ischemia-driven target-lesion revascularisation.

TCT 2021: Patients with Diabetes Undergoing PCI Have Less Target Lesion Failure with Amphilimus-Eluting Stents

Results from SUGAR, a randomised controlled, multicentre trial conducted exclusively in patients with diabetes mellitus and with minimum exclusion criteria, found that amphilimus-eluting stents (AES) were superior to zotarolimus-eluting stents (ZES) with regard to target lesion and target vessel failure composite outcomes at one year. Findings were reported Transcatheter Cardiovascular Therapeutics annual meeting (TCT 2021; 4–6 November, Orlando USA and virtual) and published simultaneously in the European Heart Journal.

Patients with diabetes are at high risk of adverse events after revascularisation with contemporary drug-eluting stents and the little evidence available for these patients suggests equivalence between most current stent types. AES are thin-strut stents eluting a formulation of sirolimus with an amphiphilic carrier from laser-dug wells on the stent’s surface that have shown positive results in previous studies in patients with diabetes.

A total of 1,175 patients with diabetes mellitus undergoing percutaneous revascularization at 23 hospitals in Spain were randomly assigned 1:1 to receive AES (n=586) or ZES (n=589). The study included all-comers and in the case of multivessel disease, all lesions were treated with the allocated stent. Baseline patient characteristics were similar among both groups.

The primary endpoint was target-lesion failure at one year, a composite of cardiac death, target-vessel myocardial infarction (MI), and ischemia-driven target-lesion revascularisation. AES met the criteria for non-inferiority compared to ZES (7.2% versus 10.9%; risk difference, -3.73% [95% CI -7.01–0.45]; p <0.001) as well as superiority (HR 0.65, 95% CI 0.44-0.96, p=0.030). The cumulative incidence of cardiac death was 2.1% for AES and 2.7% for ZES (HR 0.75, 95% CI 0.36-1.59, p=0.452). In addition, target vessel MI was 5.3% for AES compared to 7.2% for ZES (HR 0.74, 95% CI 0.44-1.23, p=0.240) and target lesion revascularisation was 2.4% for AES and 3.9% for ZES (HR 0.60, 95% CI 0.31-1.18, p=0.058).

Among the secondary endpoints, AES had a significantly lower rate of target vessel failure than ZES (7.5% versus 11.1%, HR 0.67 [95% CI 0.46-0.99], p=0.042), whereas probable or definite stent thrombosis (1.4% versus 1.4%, HR 1.00 [95% CI 0.38-2.67], p=0.994) and all-cause death (3.4% versus 5.0%, HR 0.69 [95% CI 0.39- 1.22], p=0.201) were similar in both groups.

“SUGAR is the first powered trial to compare new-generation drug-eluting stents in patients with diabetes, and also the first to include a broad population of patients with diabetes,” said Rafael Romaguera, Hospital de Bellvitge (Barcelona, Spain). “In patients with diabetes mellitus undergoing percutaneous revascularisation, the study found that amphilimus-eluting stents were superior to Onyx-zotarolimus-eluting stents with a 35% reduction in the risk of target lesion failure at one year.”

Seen on Cardiovascular News: Article Link

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

Exclusives

IoT is transforming healthcare through wearables, SaMD, and AI. MedTech needs strong branding for the efficiency and cost savings this will provide.

Digital Health

The lack of standardization is a huge problem in the diagnosis and tracking of neurological disorders: because they are so complex and often slow...

FDA

System creates 3D models of the heart with unprecedented anatomical details, allowing physicians to better plan and personalize therapeutic interventions

FDA

Linear Health Sciences has received U.S. FDA clearance and Health Canada approval of its Orchid SRV, a tension-activated breakaway safety release valve designed to reduce the...

You May Also Like

Exclusives

Plug “digital healthcare solutions” into Google, and the results are clear: digital tools have taken the healthcare industry by storm. Innovators across the HealthTech...

Exclusives

PRIA clients are provided a high-touch, white-glove service to support their patient access services.

Exclusives

In Delray Beach, Florida, an emerging biopharma company, Cyrano Therapeutics, is planning a clinical trial using approved theophylline via a new intranasal pathway of...

Exclusives

The sky’s the limit for HealthTech PR and looking past traditional strategies to nontraditional avenues for engagement will allow agencies to stand out.